Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.

BACKGROUND Elevated estradiol (E(2)) levels predispose to development of ovarian hyperstimulation syndrome (OHSS). Since GnRH antagonist is associated with a reduction in E(2) levels, we hypothesized that GnRH-antagonist treatment of women down-regulated with GnRH agonist who are at risk of OHSS might reduce E(2) levels and avoid cycle cancellation. METHODS Retrospective study in a university-based assisted reproduction technology (ART) programme in 87 patients treated with long luteal (LL) or microdose flare (MDF) with ovarian hyperresponse and 87 control patients without ovarian hyperresponse. GnRH-antagonist (ganirelix acetate) treatment was started and leuprolide acetate discontinued in women who failed to respond to a reduction in gonadotrophin dosage. RESULTS In the treatment group, there was a significant, reproducible reduction in serum E(2) levels. Mean E(2) at the start of ganirelix treatment was 4219.8 pg/ml and decreased in 24 h to 2613.7 pg/ml (36.7%; P < 0.001). An average of 24.9 +/- 8.8 oocytes were obtained at retrieval and an average of 19.1 +/- 8.0 were metaphase II (79.2%). Fertilization occurred in 13.9 +/- 8.1 embryos (72.8%). In this high risk group, two cases of severe OHSS (2.3%) occurred. The ongoing pregnancy rate was 51.8%. Compared with the control group, there were no statistically significant differences in the rate of oocyte recovery, oocyte maturity, 2PN rate, fertilization, cancellation, OHSS or pregnancy. CONCLUSIONS GnRH-antagonist treatment of women pretreated with GnRH agonist rapidly reduced circulating serum E(2) without adversely affecting oocyte maturation, fertilization rates or embryo quality and resulted in a high pregnancy rate in this subgroup of patients at risk of OHSS.

[1]  M. Dhont,et al.  Prevention of severe ovarian hyperstimulation by coasting. , 1998, Fertility and sterility.

[2]  Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation. , 1999, The Journal of clinical endocrinology and metabolism.

[3]  P. Leung,et al.  Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. , 2003, Endocrine-related cancer.

[4]  R. Lobo,et al.  Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. , 1995, Human reproduction.

[5]  C. Racowsky,et al.  Pregnancy outcomes in in vitro fertilization cycles with serum estradiol drop prior to human chorionic gonadotropin , 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[6]  Z. Rosenwaks,et al.  Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. , 2001, Fertility and sterility.

[7]  Z. Rosenwaks,et al.  Withholding gonadotropin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. , 1997, Fertility and sterility.

[8]  L. Veeck,et al.  Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. , 1997, Human reproduction.

[9]  N. Dean,et al.  Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. , 1996, Fertility and sterility.

[10]  G. Borm,et al.  Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. , 2000, Human reproduction.

[11]  P. Leung,et al.  Multi-factorial role of GnRH-I and GnRH-II in the human ovary , 2003, Molecular and Cellular Endocrinology.

[12]  Z. Rosenwaks,et al.  PROGNOSTIC ASSESSMENT OF FEMALE FECUNDITY , 1987, The Lancet.

[13]  E. Shalev,et al.  The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. , 2002, Human reproduction.

[14]  J. Grudzinskas,et al.  Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment. , 2000, Human reproduction.

[15]  M. Brännström,et al.  Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. , 1999, Fertility and sterility.

[16]  M. Sauer,et al.  Endocrinology: Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome , 1995 .

[17]  H. Tournaye,et al.  Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. , 2003, Fertility and sterility.

[18]  S. Shapiro,et al.  Plasma estradiol is superior to ultrasound and urinary estriol glucuronide as a predictor of ovarian hyperstimulation during induction of ovulation with menotropins. , 1983, Fertility and sterility.

[19]  R. Stillman,et al.  PROGNOSTIC VALUE OF DAY 3 ESTRADIOL ON IN VITRO FERTILIZATION OUTCOME , 1996 .

[20]  J. Stassart,et al.  Day 4 Estradiol Levels Predict Pregnancy Success in Women Undergoing Controlled Ovarian Hyperstimulation for IVF , 2000 .

[21]  M. Aboulghar,et al.  Prediction of ovarian hyperstimulation syndrome (OHSS). Estradiol level has an important role in the prediction of OHSS. , 2003, Human reproduction.

[22]  P. Devroey,et al.  Rescue IVF and coasting with the use of a GnRH antagonist after ovulation induction. , 2002, Reproductive biomedicine online.

[23]  L. Gianaroli,et al.  Elective cryopreservation of all pronucleate embryos in women at risk of ovarian hyperstimulation syndrome: efficiency and safety. , 1999, Human reproduction.

[24]  François Goffinet,et al.  Percentile curves of serum estradiol levels during controlled ovarian stimulation in 905 cycles stimulated with recombinant FSH show that high estradiol is not detrimental to IVF outcome. , 2002, Human reproduction.

[25]  Z. Rosenwaks,et al.  Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. , 1995, Fertility and sterility.

[26]  C. Simón,et al.  Oocyte and embryo quality after coasting: the experience from oocyte donation. , 2002, Human reproduction.

[27]  P. Kovacs,et al.  Day 6 Estradiol Level Predicts Cycle Cancellation Among Poor Responder Patients Undergoing In Vitro Fertilization—Embryo Transfer Cycles Using a Gonadotropin-Releasing Hormone Agonist Flare Regimen , 2002, Journal of Assisted Reproduction and Genetics.

[28]  P. Braude,et al.  Low serum estradiol concentrations after five days of controlled ovarian hyperstimulation for in vitro fertilization are associated with poor outcome. , 2000, Fertility and sterility.

[29]  J. Segars,et al.  Microdose follicular phase gonadotropin-releasing hormone agonist (GnRH-a) compared with luteal phase GnRH-a for ovarian stimulation at in vitro fertilization. , 1999, Fertility and sterility.

[30]  M. Matsushita,et al.  Characteristics of Population Distributions in Municipalities , 2007 .

[31]  Z. Nagy,et al.  Ganirelix acetate use in normal- and poor-prognosis patients and the impact of estradiol patterns. , 2005, Fertility and sterility.

[32]  S. Rozenberg,et al.  Is coasting effective for preventing ovarian hyperstimulation syndrome in patients receiving a gonadotropin-releasing hormone antagonist during an in vitro fertilization cycle? , 2001, Fertility and sterility.

[33]  G. Serour,et al.  Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. , 2005, Human reproduction.

[34]  J. Segars,et al.  Blastocyst transfer decreases multiple pregnancy rates in in vitro fertilization cycles: a randomized controlled trial. , 2003, Fertility and sterility.

[35]  S. Rozenberg,et al.  A qualitative systematic review of coasting, a procedure to avoid ovarian hyperstimulation syndrome in IVF patients. , 2002, Human reproduction update.

[36]  T. European Middle East Orgalutran Study Group*.  Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. , 2001, Human reproduction.

[37]  A. O. Hughes,et al.  The age-related decline in female fecundity: a quantitative controlled study of implanting capacity and survival of individual embryos after in vitro fertilization. , 1996, Fertility and sterility.

[38]  J. Itskovitz‐Eldor,et al.  Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  S. Fisher,et al.  Falling estradiol levels as a result of intentional reduction in gonadotrophin dose are not associated with poor IVF outcomes, whereas spontaneously falling estradiol levels result in low clinical pregnancy rates. , 2005, Human reproduction.

[40]  S. Stone,et al.  Severe ovarian hyperstimulation syndrome in assisted reproductive technology: definition of high risk groups. , 1991, Human reproduction.

[41]  F. Sharara,et al.  High estradiol levels and high oocyte yield are not detrimental to in vitro fertilization outcome. , 1999, Fertility and sterility.

[42]  J. Skurnick,et al.  "Coasting" does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. , 1998, Fertility and sterility.

[43]  R. Kudo,et al.  Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. , 2002, Human reproduction.

[44]  C. Gillott,et al.  Characteristics of populations of granulosa cells from individual follicles in women undergoing 'coasting' during controlled ovarian stimulation (COS) for IVF. , 2004, Human reproduction.

[45]  L. Veeck,et al.  The importance of the follicular phase to success and failure in in vitro fertilization. , 1983, Fertility and sterility.

[46]  Y. Englert,et al.  The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features. , 1993, Human reproduction.

[47]  P. Leung,et al.  Differential regulation of gonadotropin-releasing hormone (GnRH)I and GnRHII messenger ribonucleic acid by gonadal steroids in human granulosa luteal cells. , 2003, The Journal of clinical endocrinology and metabolism.